FDA Grants Accelerated Approval to Ukoniq for Previously Treated MZL and FL

The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma ...

FEBRUARY 18, 2021